Streetbeat News

Price Targets

KNX

TD Cowen analyst Jason Seidl maintains a Buy rating on Knight-Swift (NYSE:KNX) but lowers the price target from $58 to $52.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:15 pm

UAL

United Airlines shares are trading higher following price target upgrades from multiple analysts.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:13 pm

TRV

RBC Capital analyst Mark Dwelle maintains a Sector Perform rating on Travelers Companies (NYSE:TRV) and lowers the price target from $230 to $225.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:12 pm

CRSP

Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and increased the price target from $88 to $89.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:12 pm

CSX

RBC Capital analyst Walter Spracklin has maintained a 'Sector Perform' rating on CSX Corporation (NASDAQ:CSX) but lowered the price target from $37 to $36.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:03 pm

B

Barnes Group's stock price increased following an upgrade from DA Davidson, changing its rating from Neutral to Buy and raising the price target from $35 to $45.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:02 pm

TECH

In the past three months, Bio-Techne (NASDAQ:TECH) received mixed analyst ratings, with a recent shift towards a more bullish outlook. The latest assessments show 1 bullish and 1 somewhat bullish rating, with 2 indifferent ratings previously. Analysts have adjusted their 12-month price targets for TECH, now averaging $77.25, down from $87.33, reflecting a more cautious view on the company's valuation. Despite this, Bio-Techne's financial performance remains strong, with notable revenue growth and net margin, though its ROE is below industry averages.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 4:01 pm

FULT

Stephens & Co. analyst Matt Breese maintains an Equal-Weight rating on Fulton Financial (NASDAQ:FULT) and lowers the price target from $16 to $15.5.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 4:01 pm

CVNA

A comprehensive review of 12 analyst recommendations for Carvana (NYSE:CVNA) reveals a mixed sentiment, with a notable shift towards a more positive outlook in recent months. The average 12-month price target for CVNA has increased by 34.98% to $69.58, indicating analysts' growing optimism. Despite this, Carvana faces challenges such as a -14.56% decline in revenue growth and below-average ROE and ROA, alongside a high debt-to-equity ratio. The analysis includes detailed actions and adjustments by key analysts from firms like JP Morgan, JMP Securities, and Morgan Stanley.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 4:01 pm

NIC

In the past three months, Nicolet Bankshares (NYSE:NIC) received four indifferent analyst ratings, with a shift towards a negative sentiment as the average 12-month price target was decreased by 1.37% to $87.12. Analysts from Stephens & Co. and Keefe, Bruyette & Woods, among others, adjusted their price targets and ratings, reflecting recent market dynamics and company performance. Nicolet Bankshares showcases strong financial health with a market capitalization above industry average, a revenue growth rate of 9.91%, and superior net margin and ROE compared to industry benchmarks.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 4:00 pm